Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - phenobarbital - oral tablet - 60mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - phenobarbital - oral tablet - 60mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 60mg/1ml

Estats Units - anglès - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 15 mg - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance: phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence. withdrawal symptoms due to physical dependence following chronic use of large doses of barbiturates may include delirium, convulsions, and death.

Estats Units - anglès - NLM (National Library of Medicine)

c.o. truxton, inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 15 mg - phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance – phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence. withdrawal symptoms due to physical dependence following chronic use of large do

Estats Units - anglès - NLM (National Library of Medicine)

avpak - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 15 mg - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance - phenobarbital is a schedule iv drug. dependence: prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physic

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - phenobarbital - chewable tablet - 60 mg/tablet - phenobarbital - dogs - neurological preparations

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chanelle pharm. man. ltd. - phenobarbital 60 mg - tablet - 60 mg - phenobarbital 60 mg - phenobarbital - dog

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

domes pharma - phenobarbital 60 mg - tablet - 60 mg - phenobarbital 60 mg - phenobarbital - dog

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cp-pharma handelsgesellschaft gmbh - phenobarbital 60 mg - tablet - 60 mg - phenobarbital 60 mg - phenobarbital - dog